ScandiDos AB (SDOS) - Net Assets
Based on the latest financial reports, ScandiDos AB (SDOS) has net assets worth Skr41.66 Million SEK (≈ $4.48 Million USD) as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr65.97 Million ≈ $7.10 Million USD) and total liabilities (Skr24.31 Million ≈ $2.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of ScandiDos AB to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr41.66 Million |
| % of Total Assets | 63.15% |
| Annual Growth Rate | 8.62% |
| 5-Year Change | 12.0% |
| 10-Year Change | -5.32% |
| Growth Volatility | 77.62 |
ScandiDos AB - Net Assets Trend (2011–2026)
This chart illustrates how ScandiDos AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ScandiDos AB (SDOS) total market value.
Annual Net Assets for ScandiDos AB (2011–2026)
The table below shows the annual net assets of ScandiDos AB from 2011 to 2026. Also explore SDOS net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | Skr41.66 Million ≈ $4.48 Million |
-7.38% |
| 2025-04-30 | Skr44.98 Million ≈ $4.84 Million |
+1.56% |
| 2024-04-30 | Skr44.29 Million ≈ $4.77 Million |
+6.32% |
| 2023-04-30 | Skr41.65 Million ≈ $4.48 Million |
+11.98% |
| 2022-04-30 | Skr37.20 Million ≈ $4.00 Million |
-17.67% |
| 2021-04-30 | Skr45.18 Million ≈ $4.86 Million |
-2.33% |
| 2020-04-30 | Skr46.26 Million ≈ $4.98 Million |
+61.64% |
| 2019-04-30 | Skr28.62 Million ≈ $3.08 Million |
-38.56% |
| 2018-04-30 | Skr46.58 Million ≈ $5.01 Million |
+5.85% |
| 2017-04-30 | Skr44.00 Million ≈ $4.74 Million |
+37.51% |
| 2016-04-30 | Skr32.00 Million ≈ $3.44 Million |
+26.26% |
| 2015-04-30 | Skr25.34 Million ≈ $2.73 Million |
-37.40% |
| 2014-04-30 | Skr40.48 Million ≈ $4.36 Million |
+296.54% |
| 2013-04-30 | Skr10.21 Million ≈ $1.10 Million |
-17.11% |
| 2012-04-30 | Skr12.32 Million ≈ $1.33 Million |
+2.23% |
| 2011-04-30 | Skr12.05 Million ≈ $1.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ScandiDos AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52828.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.85 Million | 6.84% |
| Other Components | Skr208.07 Million | 499.42% |
| Total Equity | Skr41.66 Million | 100.00% |
ScandiDos AB Competitors by Market Cap
The table below lists competitors of ScandiDos AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Creative Global Technology Holdings Limited Ordinary Shares
NASDAQ:CGTL
|
$4.29 Million |
|
Vision Marine Technologies Inc
NASDAQ:VMAR
|
$4.30 Million |
|
Era Mandiri Cemerlang Tbk PT
JK:IKAN
|
$4.30 Million |
|
Pacte Novation
PA:MLPAC
|
$4.30 Million |
|
Accelerate Resources Ltd
AU:AX8
|
$4.29 Million |
|
BrenX Ltd.
NASDAQ:BRNX
|
$4.29 Million |
|
Project Planning Service Public Company Limited
BK:PPS
|
$4.29 Million |
|
Strategem Capital Corp
V:SGE
|
$4.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ScandiDos AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 44,980,000 to 41,662,000, a change of -3,318,000 (-7.4%).
- Net loss of 3,435,000 reduced equity.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-3.44 Million | -8.24% |
| Other Changes | Skr117.00K | +0.28% |
| Total Change | Skr- | -7.38% |
Book Value vs Market Value Analysis
This analysis compares ScandiDos AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.96x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.13x to 0.96x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-04-30 | Skr5.57 | Skr0.70 | x |
| 2012-04-30 | Skr5.69 | Skr0.70 | x |
| 2013-04-30 | Skr4.72 | Skr0.70 | x |
| 2014-04-30 | Skr2.78 | Skr0.70 | x |
| 2015-04-30 | Skr1.86 | Skr0.70 | x |
| 2016-04-30 | Skr1.68 | Skr0.70 | x |
| 2017-04-30 | Skr1.66 | Skr0.70 | x |
| 2018-04-30 | Skr1.54 | Skr0.70 | x |
| 2019-04-30 | Skr0.99 | Skr0.70 | x |
| 2020-04-30 | Skr1.12 | Skr0.70 | x |
| 2021-04-30 | Skr1.09 | Skr0.70 | x |
| 2022-04-30 | Skr0.90 | Skr0.70 | x |
| 2023-04-30 | Skr0.91 | Skr0.70 | x |
| 2024-04-30 | Skr0.97 | Skr0.70 | x |
| 2025-04-30 | Skr0.99 | Skr0.70 | x |
| 2026-04-30 | Skr0.73 | Skr0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ScandiDos AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.34%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.58x
- Recent ROE (-8.24%) is above the historical average (-24.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 2.66% | 1.11% | 1.49x | 1.62x | Skr-883.80K |
| 2012 | 1.84% | 0.63% | 1.47x | 1.98x | Skr-1.00 Million |
| 2013 | -20.50% | -5.25% | 1.35x | 2.88x | Skr-3.11 Million |
| 2014 | -10.37% | -10.85% | 0.72x | 1.33x | Skr-8.25 Million |
| 2015 | -57.94% | -44.60% | 0.76x | 1.71x | Skr-17.22 Million |
| 2016 | -44.51% | -42.42% | 0.58x | 1.80x | Skr-17.44 Million |
| 2017 | -29.90% | -27.75% | 0.75x | 1.44x | Skr-17.56 Million |
| 2018 | -24.83% | -22.87% | 0.76x | 1.42x | Skr-16.22 Million |
| 2019 | -62.06% | -36.38% | 0.71x | 2.42x | Skr-20.62 Million |
| 2020 | -28.39% | -22.93% | 0.81x | 1.53x | Skr-17.76 Million |
| 2021 | -3.10% | -2.33% | 0.78x | 1.71x | Skr-5.92 Million |
| 2022 | -19.73% | -12.72% | 0.87x | 1.78x | Skr-11.06 Million |
| 2023 | -21.89% | -14.82% | 0.85x | 1.74x | Skr-13.28 Million |
| 2024 | -33.07% | -24.24% | 0.74x | 1.84x | Skr-19.08 Million |
| 2025 | -32.56% | -24.24% | 0.82x | 1.63x | Skr-19.14 Million |
| 2026 | -8.24% | -6.34% | 0.82x | 1.58x | Skr-7.60 Million |
Industry Comparison
This section compares ScandiDos AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $773,085,954
- Average return on equity (ROE) among peers: -68.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ScandiDos AB (SDOS) | Skr41.66 Million | 2.66% | 0.58x | $4.29 Million |
| Acarix A/S (ACARIX) | $38.17 Million | -125.99% | 0.27x | $26.71 Million |
| Arcoma AB (ARCOMA) | $40.83 Million | -24.05% | 0.67x | $11.70 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $386.69 Million | 4.20% | 0.66x | $51.95 Million |
| BICO Group AB (BICO) | $6.80 Billion | -3.37% | 0.43x | $165.40 Million |
| Boule Diagnostics AB (BOUL) | $169.99 Million | 17.80% | 0.65x | $10.41 Million |
| CellaVision AB (CEVI) | $183.52 Million | 28.78% | 0.20x | $418.90 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $43.53 Million | -183.31% | 0.33x | $9.40 Million |
| Chordate Medical Holding AB (CMH) | $29.55 Million | -46.39% | 0.39x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $119.27 Million |
| Duearity AB (DEAR) | $6.06 Million | -318.56% | 0.99x | $331.97K |
About ScandiDos AB
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4… Read more